Shares of Unity Biotechnology (NASDAQ: UBX) fell over 20% today, before sharply recovering. This came after the company reported data from a phase 1 clinical trial for its lead drug candidate, UBX0101, in moderate to severe osteoarthritis. The two-part study demonstrated mixed results.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,